Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Although the immediate market response was negative, most pharmaceutical stocks recovered after Wall Street analysts ...

This investigation has raised concerns about potential legal and reputational ... the approval process for Pfizer’s vaccine candidates. Despite these challenges, Pfizer maintains a Moderate ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... rebounded after Wall Street analysts highlighted the significant legal challenges the order would face. The pharmaceutical industry has ...

The legal challenge carries a risk as well, as it could cupper the development of Enanta's drug – and possibly Pardes' – if Pfizer can prove it was the first to develop a drug candidate ...

In a landmark decision that challenges the European Commission’s transparency standards, the General Court of the European ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

May 14, 2025 Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now Biotech ... would be difficult to implement and face legal challenges. The United States and China on Monday ...

Global pharmaceutical shares jumped in intraday trading Monday, reversing their pre-market declines, as investors anticipated ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... These frameworks provide patients and developers with legal protection by simplifying liability standards for flawed ...

The pressure to strategize on its pipeline comes as Pfizer prepares for new challenges. The company is bracing for a more than $15 billion loss over the next decade as patents for six major drugs ...

Ratings for Pfizer PFE were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings ...